Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics co-development agreement with Ergomed

Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical developme...

Co-development agreement with Ergomed plc

RNS Number: 0248Z Allergy Therapeutics PLC 12 December 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics enters co-development agreement with Ergomed plc 12 December 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it h...

Holding(s) in Company

RNS Number: 7505Y Allergy Therapeutics PLC 07 December 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy ...

All resolutions passed at AGM of Allergy Therapeutics

Allergy Therapeutics has announced that all resolutions were passed by shareholders at today's Annual General Meeting. A...

All News

DateHeadlineSource
12-12-17Allergy Therapeutics co-development agreement with Ergomed StockMarketWire
12-12-17Co-development agreement with Ergomed plcRNS
07-12-17Holding(s) in CompanyRNS
22-11-17All resolutions passed at AGM of Allergy TherapeuticsStockMarketWire
22-11-17Result of AGMRNS
21-11-17Block Listing ApplicationRNS
13-11-17Allergy Therapeutics to Present at Jefferies 2017RNS
07-11-17Director/PDMR ShareholdingRNS
07-11-17Director/PDMR ShareholdingRNS
19-10-17Publication of Annual Report and notice of AGMRNS
19-10-17Allergy Therapeutics starts dosing for grass pollen trial StockMarketWire
19-10-17Commencement of dosing in PQ Grass Phase II TrialRNS
12-10-17Holding(s) in CompanyRNS
12-10-17Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
12-10-17Director/PDMR ShareholdingRNS
10-10-17Allergy Therapeutics 'continuing to gain market share'StockMarketWire
10-10-17Hardman Research: Continuing to gain market shareRNS
28-09-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
28-09-17Allergy Therapeutics pre-tax losses narrow StockMarketWire
28-09-17Preliminary ResultsRNS
18-09-17Allergy Therapeutics gets approval for PQ Grass trial StockMarketWire
18-09-17Approval for PQ Grass Phase II trialRNS
11-09-17Allergy Therapeutics expands R&D and clinical team StockMarketWire
11-09-17Expansion of Clinical Development and R&D teamsRNS
15-08-17 Allergy Therapeutics schedules FY results StockMarketWire
15-08-17Notice of ResultsRNS
18-07-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
18-07-17Allergy Therapeutics ahead of forecasts StockMarketWire
18-07-17Trading UpdateRNS
06-07-17Publication of adjuvant studies in journalsRNS
27-06-17Investor and analyst site visitsRNS
19-06-17Allergy Therapeutics hosts satellite symposium at EAACIStockMarketWire
19-06-17Satellite Symposium at EAACI 2017RNS
06-06-17Directorate changesRNS
02-06-17Holding(s) in CompanyRNS
13-04-17Issue of EquityRNS
05-04-17Hardman Research: Development across portfolioRNS
04-04-17Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
29-03-17Interim Results for six months ended 31 Dec 2016RNS
16-03-17Allergy Therapeutics recruits first patient in birch pollen trial StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account